Associated Papers
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.
Kucharczyk T et al.
Cancers, 2022
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
RET kinase inhibitors for RET-altered thyroid cancers.
Vodopivec DM et al.
Therapeutic Advances in Medical Oncology, 2022
Select a paper to view details